We are live on ! Find out more

Neurocrine Biosciences

NBIX

Market cap $15.1B

148.61 USD

+2.23

1.52%

At close Updated Oct 30, 10:52 AM EDT

1 day

1.52%

5 days

3.21%

1 month

4.77%

3 months

-19.89%

6 months

12.87%

Year to date

5.7%

1 year

7.66%

5 years

39.91%

10 years

239.52%

About: Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Employees: 2,500

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.3%

Neutral 57.1%

Negative 8.6%

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

BootCAHmp® delivers evidence-based education to strengthen understanding of classic congenital adrenal hyperplasia through interactive learning and real-world patient cases DiscoverCAH™ provides immersive virtual experiences to expand knowledge of classic congenital adrenal hyperplasia through realistic patient scenarios SAN DIEGO, Oct. 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of educational resources designed to help healthcare providers strengthen their understanding of classic congenital adrenal hyperplasia. The offerings include bootCAHmp ®, an interactive, educational course that builds foundational clinical knowledge, and DiscoverCAH ™, a virtual patient case experience that enables healthcare providers to apply their knowledge of the condition through realistic clinical decision-making scenarios.

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

Zacks Investment Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine) capsules The 6-point threshold helps contextualize the meaningful improvement with INGREZZA observed in the KINECT-PRO™ study, including a mean 13.1-point improvement in EQ Visual Analogue Scale scores, and complements established measures of tardive dyskinesia-specific impact and movement severity Findings are among three Neurocrine Biosciences analyses to be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference SAN DIEGO, Oct. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with INGREZZA® (valbenazine) capsules. The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, taking place Oct. 26-29 in San Diego.

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

The Motley Fool

Where Will Neurocrine Biosciences Be in 5 Years?

Ingrezza remains Neurocrine's biggest revenue driver, with sales growing 15%. Two late-stage drug candidates face important clinical milestones in 2027.

Where Will Neurocrine Biosciences Be in 5 Years?

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for patients and families beyond obesity-related complications The manuscript underscores the importance of multidimensional assessment and integrated care management across the patient lifespan Experts conclude VYKAT® XR (diazoxide choline) extended-release tablets represent a significant advancement in the treatment of hyperphagia, potentially complementing behavioral and environmental approaches SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a publication of expert perspectives highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition that extends beyond excessive hunger and requires comprehensive assessment and management across the patient lifespan. The publication provides insights from an international group of clinical and scientific experts on the evolving understanding of hyperphagia and its implications for the care of people with PWS.

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease. NBI-'567 is an orally administered, M1/M4 (M1 preferring) selective muscarinic agonist being evaluated as an adjunctive treatment for cognitive impairment in Alzheimer's disease.

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-age monitoring in childhood; puberty and reproductive health concerns through adolescence and young adulthood; and increasingly diverse clinical needs in adulthood, while treatment and self-management demands persisted across life stages The analysis captured impacts beyond traditional medical complications, including daily activities, school, work, caregiving, self-management, and access to care Mapping patient experiences over time may help healthcare professionals anticipate evolving needs and inform education, support strategies, and coordination across care teams SAN DIEGO, Oct. 16, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient's life. The findings will be presented at the Endocrine Nurses Society Annual Symposium 2026, taking place Oct. 16-17 in Phoenix.

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

Zacks Investment Research

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term

Zacks Investment Research

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term

See News Rankings

Price charts implemented using Lightweight Charts™